Shares of Provention Bio soared Monday after the biopharmaceutical company agreed to be acquired by France’s Sanofi (SNY) for $25 a share, or about $2.9 billion. Provention Bio (ticker: PRVB), which f...
Tag: Biotechnology Services
First Republic, Provention Bio, Roku, Illumina, Boeing, and More Market Movers
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barro...
This is what Warren Buffett, a self-described ‘so-so investor,’ says is his ‘secret sauce’
Stocks are rebounding on the heels of a rotten week — the worst since December for the S&P 500 SPX, +1.15% and the Nasdaq Composite COMP, +1.39%. And as Wall Street analysts go dark, with talk of ...
Crispr Therapeutics: FDA Filing on Sickle Cell Gene Therapy Is Almost Done
An approval filing for a breakthrough treatment of sickle cell disease should be done by March, Crispr Therapeutics said, highlighting the company’s lead in a competitive area of medical research and ...
Here are five companies to pick if Goldman Sachs is right about the stock market being flat in 2023
Hearts, flowers and CPI data. Get ready for Tuesday. And hell hath no fury like a disappointed Wall Street. The last time CPI let the markets down — last September — stocks melted down like chocolate....
CureVac Stock Just Got Upgraded. It’s Now a Competitor in mRNA Vaccines.
CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise. UBS analyst Eliana Merle upgraded the shares (ticker: CVA...
Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.
Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon. With real...
Opinion: The stock market is telling you loud and clear: Now is not the time to fight the Fed or stand up to the bears.
The S&P 500 Index SPX, -1.85% hit resistance this week when an oversold rally failed near the 4080 level. This continues to support the idea that the index’s rise above 4100 in early February was ...